BioCentury | Apr 16, 2012
Finance

Heeding health economics

...for $225 million in cash, plus up to $300 million in milestones, in 2011; and Salmedix Inc....
BioCentury | Jan 19, 2009
Strategy

Cephalon's shopping spree

...plus royalties, from Cell Therapeutics Inc. That same month, the company completed the acquisition of Salmedix Inc....
BioCentury | Jun 4, 2007
Finance

Ebb & Flow

...strategic consulting practice, and prior to that was co-founder, chairman and CEO of cancer company Salmedix...
BioCentury | Oct 2, 2006
Company News

Rx3 board of directors update

...Julia Brown, a former EVP at Amylin Pharmaceuticals Inc. ; David Kabakoff, former CEO of Salmedix Inc....
BioCentury | Apr 10, 2006
Strategy

Top private takeouts

...Cash 2005 Johnson & Johnson TransForm $230 Cash 2006 AstraZeneca KuDos $210 Cash 2005 Cephalon Salmedix...
BioCentury | Mar 20, 2006
Company News

Tracon Pharmaceutics Inc. management update

...Group; and Elizabeth Moore as VP of regulatory affairs, formerly VP of regulatory affairs at Salmedix Inc. WIR...
BioCentury | Dec 13, 2005
Clinical News

Cephalon reports Phase II NHL, AML data

...and a 39% partial response rate. CEPH gained the alkylating agent through its acquisition of Salmedix...
BioCentury | Dec 5, 2005
Company News

InterMune board of directors update

...ITMN), Brisbane, Calif. Business: Musculoskeletal, Infectious, Pulmonary Appointed: David Kabakoff, former chairman and CEO of Salmedix Inc. WIR...
BioCentury | Aug 8, 2005
Finance

EPS watch

...$40.97 -$0.93 -2% -$54.0 $2,378.1 EPS excludes charges of $290.1M related to CEPH's acquisition of Salmedix...
BioCentury | Aug 3, 2005
Financial News

Cephalon beats Street

...of 2004. CEPH's EPS excludes charges of $290.1 million related to the company's acquisition of Salmedix...
Items per page:
1 - 10 of 46
BioCentury | Apr 16, 2012
Finance

Heeding health economics

...for $225 million in cash, plus up to $300 million in milestones, in 2011; and Salmedix Inc....
BioCentury | Jan 19, 2009
Strategy

Cephalon's shopping spree

...plus royalties, from Cell Therapeutics Inc. That same month, the company completed the acquisition of Salmedix Inc....
BioCentury | Jun 4, 2007
Finance

Ebb & Flow

...strategic consulting practice, and prior to that was co-founder, chairman and CEO of cancer company Salmedix...
BioCentury | Oct 2, 2006
Company News

Rx3 board of directors update

...Julia Brown, a former EVP at Amylin Pharmaceuticals Inc. ; David Kabakoff, former CEO of Salmedix Inc....
BioCentury | Apr 10, 2006
Strategy

Top private takeouts

...Cash 2005 Johnson & Johnson TransForm $230 Cash 2006 AstraZeneca KuDos $210 Cash 2005 Cephalon Salmedix...
BioCentury | Mar 20, 2006
Company News

Tracon Pharmaceutics Inc. management update

...Group; and Elizabeth Moore as VP of regulatory affairs, formerly VP of regulatory affairs at Salmedix Inc. WIR...
BioCentury | Dec 13, 2005
Clinical News

Cephalon reports Phase II NHL, AML data

...and a 39% partial response rate. CEPH gained the alkylating agent through its acquisition of Salmedix...
BioCentury | Dec 5, 2005
Company News

InterMune board of directors update

...ITMN), Brisbane, Calif. Business: Musculoskeletal, Infectious, Pulmonary Appointed: David Kabakoff, former chairman and CEO of Salmedix Inc. WIR...
BioCentury | Aug 8, 2005
Finance

EPS watch

...$40.97 -$0.93 -2% -$54.0 $2,378.1 EPS excludes charges of $290.1M related to CEPH's acquisition of Salmedix...
BioCentury | Aug 3, 2005
Financial News

Cephalon beats Street

...of 2004. CEPH's EPS excludes charges of $290.1 million related to the company's acquisition of Salmedix...
Items per page:
1 - 10 of 46